Mobile

Long-term persistence of hepatitis B antibodies and immune response to a challenge dose of GSK Biologicals’ HBV vaccine, Engerix™-B Kinder (SKF103860), in 15-16 years old adolescents, vaccinated in in...

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-003950-10

Long-term persistence of hepatitis B antibodies and immune response to a challenge dose of GSK Biologicals’ HBV vaccine, Engerix™-B Kinder (SKF103860), in 15-16 years old adolescents, vaccinated in infancy with Engerix™-B Kinder

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the anti-HBs antibody response to a challenge dose of Engerix-B Kinder in subjects 15-16 years of age vaccinated with three doses of Engerix-B Kinder in infancy.

Critère d'inclusion

  • Hepatitis

Liens